First Eagle Investment Management LLC Has $6.91 Million Holdings in CareDx, Inc. $CDNA

First Eagle Investment Management LLC lifted its holdings in shares of CareDx, Inc. (NASDAQ:CDNA) by 25.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 475,146 shares of the company’s stock after purchasing an additional 96,123 shares during the quarter. First Eagle Investment Management LLC’s holdings in CareDx were worth $6,909,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Rafferty Asset Management LLC lifted its holdings in shares of CareDx by 29.6% in the third quarter. Rafferty Asset Management LLC now owns 92,498 shares of the company’s stock valued at $1,345,000 after purchasing an additional 21,129 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of CareDx in the 3rd quarter valued at approximately $89,000. Palumbo Wealth Management LLC acquired a new stake in CareDx in the third quarter valued at $538,000. Zweig DiMenna Associates LLC lifted its stake in CareDx by 153.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 575,000 shares of the company’s stock valued at $8,360,000 after purchasing an additional 348,400 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of CareDx during the 3rd quarter worth approximately $446,000.

Analysts Set New Price Targets

Several analysts recently commented on the stock. BTIG Research lifted their target price on shares of CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a research note on Tuesday, January 6th. Weiss Ratings cut CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, February 27th. Finally, Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CareDx currently has an average rating of “Hold” and an average price target of $27.33.

CareDx Price Performance

NASDAQ CDNA opened at $19.06 on Thursday. CareDx, Inc. has a one year low of $10.96 and a one year high of $21.49. The business’s fifty day moving average is $19.58 and its 200-day moving average is $16.99. The stock has a market capitalization of $976.25 million, a price-to-earnings ratio of -47.65 and a beta of 2.52.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The business’s quarterly revenue was up 25.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.18 earnings per share. Research analysts expect that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares in the company, valued at $12,641,089.80. This represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 29,636 shares of company stock worth $625,949. 4.40% of the stock is owned by insiders.

CareDx Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.